The trial will evaluate the safety and effectiveness of a next-generation vaccine administered through a nasal spray or inhalation. A nasal COVID-19 vaccine, developed using technology from Washington ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...

A nasal vaccine for COVID-19 – based on technology developed at Washington University in St. Louis – is poised to enter a phase 1 clinical trial in the U.S. after an investigational new drug ...

A new scoping review examines the impact of respiratory bacteria on the severity of respiratory syncytial virus (RSV) ...

During the COVID pandemic, RSV showed a slightly odd pattern: like flu, it basically disappeared in the 2020–2021 season, ...

The technology could be adapted for other common respiratory viruses such as seasonal influenza, avian flu and respiratory syncytial virus (RSV ... also a professor of molecular microbiology and of ...

Respiratory virus data included in the interactive data application is up-to-date as of Feb 1, 2025. Among its new features, the dashboard now includes RSV Severe Outcomes data.

No writing assistance was utilized in the production of this manuscript. Worldwide, respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants.

In the UK, they’re calling it the “Four Soar.” But whatever you call it, it’s bad news. Influenza, COVID-19, respiratory syncytial virus (RSV) and norovirus are all making folks miserable at the ...

The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days of vaccination ...